Pharmaceuticals and crop protection firm Hikal Ltd reported a consolidated net loss of ₹7.4 crore for the first quarter, representing a significant improvement from the net loss of ₹22.4 crore recorded in the corresponding period last year. According to latest reports from Business Standard, the company demonstrated strong operational performance with revenue rising 31% year-on-year to ₹399.80 crore from ₹371.30 crore in the previous year, showing consistent growth momentum across quarters.
The company's Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) increased 49% to ₹36.6 crore compared with ₹24.6 crore in the year-ago period. As reported by CNBC TV18, EBITDA margin expanded to 9% during the quarter from 6.5% a year earlier, indicating improved operational efficiency and cost management. This margin expansion demonstrates the company's ability to enhance profitability despite the continued net loss position.
Despite the positive financial results, Hikal Ltd shares ended at ₹216.60, down by ₹15.55, or 6.70% on the BSE on Thursday (August 6), according to CNBC TV18. The market reaction suggests that investors may have been focusing on other factors beyond the quarterly financial performance, or the positive results may not have met market expectations for the pharmaceuticals and crop protection company.
